Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies M Dostalek, I Gardner, BM Gurbaxani, RH Rose, M Chetty Clinical pharmacokinetics 52, 83-124, 2013 | 250 | 2013 |
Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome M Bebawy, M Chetty Current drug metabolism 10 (4), 322-328, 2009 | 88 | 2009 |
Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1‐Related Variability in Pharmacodynamics of Rosuvastatin RH Rose, S Neuhoff, K Abduljalil, M Chetty, A Rostami‐Hodjegan, ... CPT: pharmacometrics & systems pharmacology 3 (7), 1-9, 2014 | 83 | 2014 |
Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics KL Gill, KK Machavaram, RH Rose, M Chetty Clinical pharmacokinetics 55 (7), 789-805, 2016 | 81 | 2016 |
CYP-mediated clozapine interactions: how predictable are they? M Chetty, M Murray Current drug metabolism 8 (4), 307-313, 2007 | 65 | 2007 |
Physiologically based pharmacokinetic modelling to guide drug delivery in older people M Chetty, TN Johnson, S Polak, F Salem, K Doki, A Rostami-Hodjegan Advanced Drug Delivery Reviews 135, 85-96, 2018 | 64 | 2018 |
Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug … M Chetty, RH Rose, K Abduljalil, N Patel, G Lu, T Cain, M Jamei, ... Frontiers in pharmacology 5, 258, 2014 | 61 | 2014 |
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz P Naidoo, VV Chetty, M Chetty European journal of clinical pharmacology 70, 379-389, 2014 | 52 | 2014 |
A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients S Ghassabian, M Chetty, BN Tattam, J Glen, J Rahme, Z Stankovic, ... Therapeutic drug monitoring 31 (2), 239-246, 2009 | 50 | 2009 |
Psychotropic drug interactions with valproate J Fleming, M Chetty Clinical neuropharmacology 28 (2), 96-101, 2005 | 49 | 2005 |
Smoking and body weight influence the clearance of chlorpromazine. M Chetty, R Miller, SV Moodley European journal of clinical pharmacology 46 (6), 523-526, 1994 | 48 | 1994 |
Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus M Chetty, D Mattison, A Rostami-Hodjegan Current drug metabolism 13 (6), 778-786, 2012 | 45 | 2012 |
Therapeutic monitoring of valproate in psychiatry: how far have we progressed? J Fleming, M Chetty Clinical neuropharmacology 29 (6), 350-360, 2006 | 39 | 2006 |
Prediction of the pharmacokinetics, pharmacodynamics, and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model M Chetty, L Li, R Rose, K Machavaram, M Jamei, A Rostami-Hodjegan, ... Frontiers in Immunology 5, 670, 2015 | 32 | 2015 |
Phenytoin auto-induction M Chetty, R Miller, MA Seymour Therapeutic drug monitoring 20 (1), 60-62, 1998 | 32 | 1998 |
Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia M Bebawy, M Chetty Bioessays 30 (2), 183-188, 2008 | 28 | 2008 |
Are standard doses of renally-excreted antiretrovirals in older patients appropriate: a PBPK study comparing exposures in the elderly population with those in renal impairment M De Sousa Mendes, M Chetty Drugs in R&D 19 (4), 339-350, 2019 | 25 | 2019 |
Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site H Musther, KL Gill, M Chetty, A Rostami-Hodjegan, M Rowland, M Jamei The AAPS journal 17, 1268-1279, 2015 | 22 | 2015 |
The use of a side effect as a qualitative indicator of plasma chlorpromazine levels M Chetty, E Gouws, R Miller, SV Moodley European neuropsychopharmacology 9 (1-2), 77-82, 1999 | 21 | 1999 |
Dosing and therapeutic monitoring of phenytoin in young adults after neurotrauma: are current practices relevant? V Frend, M Chetty Clinical neuropharmacology 30 (6), 362-369, 2007 | 19 | 2007 |